Product Description
TYK Medicines is developing ty-9591, an Oral EGFR Inhibitor for Advanced NSCLC Patients With Epidermal Growth factor Receptor( EGfR) Positive Mutation
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TYK Medicines
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 12
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 2: Brain Cancer|Meningeal Carcinomatosis
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05948813 |
TYKM1601202 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Brain Cancer|Small Cell Lung Cancer |
2025-06-30 |
73% |
2023-10-18 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT05146219 |
TYKM1601201 | P2 |
Completed |
Brain Cancer|Small Cell Lung Cancer|Meningeal Carcinomatosis|Non-Small-Cell Lung Cancer |
2024-03-21 |
31% |
2025-01-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06672068 |
TYKM1601203 | P2 |
Not yet recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2027-12-01 |
2% |
2024-11-05 |
Primary Endpoints|Treatments |
CTR20192665 |
CTR20192665 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2023-05-18 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT04204473 |
TYKM1601101 | P1 |
Completed |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2023-03-03 |
12% |
2023-11-19 |
Primary Completion Date|Primary Endpoints |
CTR20212878 |
CTR20212878 | P2 |
Completed |
Brain Cancer|Non-Small-Cell Lung Cancer |
2024-11-13 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20244968 |
CTR20244968 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
None |
2025-11-09 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20231808 |
CTR20231808 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer|Brain Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20240588 |
CTR20240588 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-05-23 |
2025-04-29 |
||
NCT05382728 |
FLETEO | P3 |
Recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2025-05-01 |
30% |
2022-12-08 |
Primary Endpoints|Start Date|Treatments|Trial Status |
CTR20231398 |
CTR20231398 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-01-29 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05871905 |
TYKM1601103 | P1 |
Completed |
Healthy Volunteers |
2023-11-06 |
69% |
2025-01-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|